Advanced prostate cancer remains a leading cause of cancer death among men. As the therapeutic landscape evolved to include combination therapies for gene mutated disease, with response to PARP inhibitors hinging on detecting germline or somatic DNA-repair defects, professional societies endorse universal germline testing plus broad next-generation sequencing once metastatic disease is diagnosed. In this video-based activity, leading experts explore germline and somatic testing indications, panels, and workflows that detect DDR/HRR alterations relevant to PARP-inhibitor use. This activity also addresses evidence for sequencing PARP inhibitors with ARPIs, taxanes, radioligand therapy, and immunotherapy in mHSPC and mCRPC and offers strategies for evaluating patient- and disease-specific factors when considering prostate-directed radiotherapy or cytoreductive surgery alongside systemic PARP-based regimens. This activity also focuses on shared-decision frameworks that incorporate patient-reported outcomes and tips for overcoming financial toxicity and other barriers to optimal outcomes.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
All courses included · $249.99 – $299.99/yr
Courses are included in the subscription; some are also sold individually.
Collected from the provider’s public pages · source
Top 6 courses
-
-
Fractures
4 Credits
-
-
Putting Care at the Center 2026
14.5 Credits
-
-
Specialties served/covered
- Addiction Medicine
- Addiction Psychiatry
- Adolescent Medicine
- Cardiovascular Disease
- Clinical Cardiac Electrophysiology
- Clinical Informatics
- Clinician Wellness & Burnout
- Communication & Shared Decision-Making
- Comprehensive & Board Review
- Critical Care Medicine
- Dermatology
- Diagnostic Radiology
- Emergency Medicine
- Endocrinology, Diabetes & Metabolism
- Evidence-Based Medicine & Research
- Facial Plastic & Reconstructive Surgery
- Family Medicine
- Female Pelvic Medicine & Reconstructive Surgery
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- General Pediatrics
- General Surgery
- Geriatric Medicine
- Geriatric Psychiatry
- Health Equity & Inclusion
- Hematology
- Hospital Medicine
- Infectious Disease
- Interventional Radiology
- Maternal-Fetal Medicine
- Medical Leadership & Administration
- Medical Oncology
- Mood & Anxiety Disorders
- Neonatal-Perinatal Medicine
- Nephrology
- Neurocritical Care
- Neurology
- Neuroradiology
- Nuclear Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Orthopaedic Surgery
- Pain Medicine
- Patient Safety & Quality Improvement
- Pediatric Critical Care Medicine
- Pediatric Emergency Medicine
- Pediatric Gastroenterology
- Pediatric Neurology
- Plastic & Reconstructive Surgery
- Practice Management & Ethics
- Preventive Medicine
- Primary Care Sports Medicine
- Psychotic Disorders
- Pulmonary Disease
- Radiation Oncology
- Regional Anesthesia & Acute Pain
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Thoracic Surgery
- Transplant Hepatology
- Transplant Surgery
- Urological Oncology
- Urology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- ENT & Head Neck
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Orthopedics
- Pain & Palliative
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Sports & Exercise Medicine
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- On-demand / recorded video
- Credit · Up to 2.25 credits
- Commercial Support
-
ReleasedAug 14, 2026
-
Last day to claim creditAug 15, 2027 10 months left
-
PRIME Education, Inc. (PRIME®) Advancing Immune Checkpoint Inhibitor Use in Resectable Melanoma
-
Plexus Communications +1 Optimizing Checkpoint Inhibitor Therapy for Advanced Hepatobiliary Cancers
-
International Society on Thrombosis and Haemostasis +1 Perspectives: What We Are Learning From FXI/FXIa Inhibitor Trials
-
StitchedHealth, Inc. +1 Optimizing Comprehensive Molecular Profiling in Advanced NSCLC: A Full Circle Learning Experience to Close the Testing-to-Treatment Gap.
-
Postgraduate Healthcare Education, LLC +1 Optimizing the 1L Management of Advanced Renal Cell Carcinoma: Focus on the Evolving Evidence and Best Practices for ICI-TKI Combinations
-
BackTable +1 Partnering for Progress: Co-managed Clinics and Patient-Centered Treatment Sequencing in NMIBC
